Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
July 28, 2011
Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
The patent, EP1633890, is part of the so-called Zamore IP estate and claims rules for designing RNAi molecules with improved potency and fewer off-target effects.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- USPTO Upholds Silence's 'Zamore Design Rules' Patents
December 15, 2011 / Gene Silencing News - Alnylam Files Opposition Against Silence Patent in Europe
November 18, 2010 / Gene Silencing News - Silence Responds to Alnylam European Patent Claims
March 15, 2012 / Gene Silencing News - Alnylam Execs Downplay Importance of Silence Therapeutics' Zamore IP
August 12, 2010 / Gene Silencing News - Alnylam RNAi IP Upheld in European Opposition Proceedings
December 2, 2010 / Gene Silencing News